Ticker: FATE

Company: FATE THERAPEUTICS INC

Person: ROBERT S EPSTEIN, director

Transaction date: May 5, 2026

Reporting date: May 6, 2026

Average share price: 1.69

Bought 25000.0 shares for 42250.0